[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fOwsSKM3PAlNp3ZJyHtJOnDoBo9vUKE8m_rFriT8HQuY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Cardenal Herrera University",[4],102,false,18,1,7935,4,101,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Obesity",7,{"name":18,"count":19},"End Stage Renal Disease",6,{"name":21,"count":19},"Low Back Pain",{"name":23,"count":24},"Hypertension",5,{"name":26,"count":27},"Fibromyalgia",3,{"name":29,"count":27},"Sarcopenia",{"name":31,"count":27},"End Stage Renal Disease on Dialysis",{"name":33,"count":34},"Knee Osteoarthritis",2,[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07309094","Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","2027-07-31","GLP-1 receptor agonist",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,80,98,116],{"intervention":40,"totalTrials":9,"cells":50},{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":58,"PHASE4":60,"NA":62},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[],{"trials":59,"activeCount":53},[],{"trials":61,"activeCount":53},[],{"trials":63,"activeCount":9,"soonestReadout":39},[64],{"nctId":37,"briefTitle":38,"status":65,"phases":66,"primaryCompletion":39,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":76},"RECRUITING",[],"2028-12-31","2023-09-15",250,[71,72,73,74,15,75],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Chronic Kidney Disease Stage 1","Chronic Kidney Disease Stage 2","Diabetes Mellitus, Type 2",[40,77,78,79],"SGLT2 inhibitor","Tirzepatide","Other drugs",{"intervention":77,"totalTrials":9,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":92},{"trials":83,"activeCount":53},[],{"trials":85,"activeCount":53},[],{"trials":87,"activeCount":53},[],{"trials":89,"activeCount":53},[],{"trials":91,"activeCount":53},[],{"trials":93,"activeCount":9,"soonestReadout":39},[94],{"nctId":37,"briefTitle":38,"status":65,"phases":95,"primaryCompletion":39,"completion":67,"start":68,"enrollment":69,"conditions":96,"interventions":97},[],[71,72,73,74,15,75],[40,77,78,79],{"intervention":78,"totalTrials":9,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":101,"activeCount":53},[],{"trials":103,"activeCount":53},[],{"trials":105,"activeCount":53},[],{"trials":107,"activeCount":53},[],{"trials":109,"activeCount":53},[],{"trials":111,"activeCount":9,"soonestReadout":39},[112],{"nctId":37,"briefTitle":38,"status":65,"phases":113,"primaryCompletion":39,"completion":67,"start":68,"enrollment":69,"conditions":114,"interventions":115},[],[71,72,73,74,15,75],[40,77,78,79],{"intervention":79,"totalTrials":9,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":53},[],{"trials":121,"activeCount":53},[],{"trials":123,"activeCount":53},[],{"trials":125,"activeCount":53},[],{"trials":127,"activeCount":53},[],{"trials":129,"activeCount":9,"soonestReadout":39},[130],{"nctId":37,"briefTitle":38,"status":65,"phases":131,"primaryCompletion":39,"completion":67,"start":68,"enrollment":69,"conditions":132,"interventions":133},[],[71,72,73,74,15,75],[40,77,78,79]]